Coherus Oncology, Inc. (FRA:8C5)
Germany · Delayed Price · Currency is EUR 1.440
+0.075 (5.46%)
At close: Feb 20, 2026
Coherus Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 277.73 | 266.96 | 257.24 | 211.04 | 326.55 | 475.82 |
Revenue | 277.73 | 266.96 | 257.24 | 211.04 | 326.55 | 475.82 |
Revenue Growth (YoY) | 152.07% | 3.78% | 21.89% | -35.37% | -31.37% | 33.63% |
Cost of Revenue | 121.35 | 117.55 | 158.99 | 70.08 | 57.59 | 37.67 |
Gross Profit | 156.38 | 149.41 | 98.25 | 140.96 | 268.96 | 438.16 |
Selling, General & Admin | 140.06 | 150.44 | 185.62 | 198.48 | 169.71 | 139.08 |
Research & Development | 100.18 | 93.34 | 105.84 | 199.36 | 363.11 | 142.76 |
Operating Expenses | 240.24 | 243.77 | 291.45 | 397.84 | 532.82 | 281.84 |
Operating Income | -83.85 | -94.37 | -193.2 | -256.88 | -263.86 | 156.32 |
Interest Expense | -25.09 | -27.16 | -40.54 | -32.47 | -22.96 | -21.17 |
Interest & Investment Income | 4.5 | 4.5 | 2.8 | 1.9 | 1.4 | 0.6 |
Other Non Operating Income (Expenses) | -2.32 | -1.13 | 2.67 | 1.92 | -1.68 | -0.05 |
EBT Excluding Unusual Items | -106.76 | -118.15 | -228.27 | -285.53 | -287.1 | 135.71 |
Merger & Restructuring Charges | -6.7 | -6.7 | -10 | - | - | - |
Gain (Loss) on Sale of Assets | 176.59 | 176.59 | - | - | - | - |
Asset Writedown | -2.1 | -10.6 | - | - | - | - |
Other Unusual Items | - | -12.63 | - | -6.22 | - | - |
Pretax Income | 61.03 | 28.51 | -238.27 | -291.75 | -287.1 | 135.71 |
Income Tax Expense | - | - | -0.38 | - | - | 3.46 |
Earnings From Continuing Operations | 61.03 | 28.51 | -237.89 | -291.75 | -287.1 | 132.24 |
Net Income | 154.97 | 28.51 | -237.89 | -291.75 | -287.1 | 132.24 |
Net Income to Common | 154.97 | 28.51 | -237.89 | -291.75 | -287.1 | 132.24 |
Net Income Growth | - | - | - | - | - | 47.21% |
Shares Outstanding (Basic) | 116 | 115 | 94 | 78 | 75 | 71 |
Shares Outstanding (Diluted) | 116 | 115 | 94 | 78 | 75 | 83 |
Shares Change (YoY) | 2.22% | 21.95% | 21.30% | 2.89% | -9.63% | 14.08% |
EPS (Basic) | 1.34 | 0.25 | -2.53 | -3.76 | -3.81 | 1.85 |
EPS (Diluted) | 1.34 | 0.25 | -2.53 | -3.76 | -3.81 | 1.62 |
EPS Growth | - | - | - | - | - | 31.99% |
Free Cash Flow | -90.19 | -20.44 | -174.88 | -241.12 | -38.72 | 146.91 |
Free Cash Flow Per Share | -0.78 | -0.18 | -1.86 | -3.11 | -0.51 | 1.76 |
Gross Margin | 56.31% | 55.97% | 38.19% | 66.79% | 82.36% | 92.08% |
Operating Margin | -30.19% | -35.35% | -75.10% | -121.72% | -80.80% | 32.85% |
Profit Margin | 55.80% | 10.68% | -92.48% | -138.25% | -87.92% | 27.79% |
Free Cash Flow Margin | -32.47% | -7.66% | -67.98% | -114.25% | -11.86% | 30.88% |
EBITDA | -79.79 | -89.09 | -189.41 | -253.18 | -260.4 | 159.21 |
EBITDA Margin | -28.73% | -33.37% | -73.63% | -119.97% | -79.74% | 33.46% |
D&A For EBITDA | 4.06 | 5.28 | 3.79 | 3.7 | 3.45 | 2.89 |
EBIT | -83.85 | -94.37 | -193.2 | -256.88 | -263.86 | 156.32 |
EBIT Margin | -30.19% | -35.35% | -75.10% | -121.72% | -80.80% | 32.85% |
Effective Tax Rate | - | - | - | - | - | 2.55% |
Advertising Expenses | - | 10.9 | 10.9 | 10.5 | - | 3.8 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.